Use of alprenolol in acute cardiac arrhythmias

Louis Lemberg, Azucena G. Arcebal, Agustin Castellanos, Douglas Slavin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Alprenolol, a new beta adrenergic receptor blocking agent, was evaluated as an antiarrhythmic drug in 49 patients with 78 episodes of premature contractions or tachyarrhythmias of supraventricular or ventricular origin. A clinically and statistically significant reduction in frequency of premature contractions was obtained. In addition, a clinically and statistically significant reduction in ventricular rate occurred in those patients with tachyarrhythmias. No severe adverse effects were noted during the study. The results indicate that alprenolol can be used safely and effectively in the treatment of cardiac arrhythmias occurring during acute myocardial infarction. Congestive heart failure was not considered a contraindication when it was judged clinically that the arrhythmia aggravated the heart failure.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalThe American journal of cardiology
Volume30
Issue number1
DOIs
StatePublished - Jul 11 1972

Fingerprint

Alprenolol
Tachycardia
Cardiac Arrhythmias
Heart Failure
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Receptors, Adrenergic, beta
Myocardial Infarction
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lemberg, L., Arcebal, A. G., Castellanos, A., & Slavin, D. (1972). Use of alprenolol in acute cardiac arrhythmias. The American journal of cardiology, 30(1), 77-81. https://doi.org/10.1016/0002-9149(72)90129-4

Use of alprenolol in acute cardiac arrhythmias. / Lemberg, Louis; Arcebal, Azucena G.; Castellanos, Agustin; Slavin, Douglas.

In: The American journal of cardiology, Vol. 30, No. 1, 11.07.1972, p. 77-81.

Research output: Contribution to journalArticle

Lemberg, L, Arcebal, AG, Castellanos, A & Slavin, D 1972, 'Use of alprenolol in acute cardiac arrhythmias', The American journal of cardiology, vol. 30, no. 1, pp. 77-81. https://doi.org/10.1016/0002-9149(72)90129-4
Lemberg, Louis ; Arcebal, Azucena G. ; Castellanos, Agustin ; Slavin, Douglas. / Use of alprenolol in acute cardiac arrhythmias. In: The American journal of cardiology. 1972 ; Vol. 30, No. 1. pp. 77-81.
@article{a94bb194773149e1bd0b4ce1154f656f,
title = "Use of alprenolol in acute cardiac arrhythmias",
abstract = "Alprenolol, a new beta adrenergic receptor blocking agent, was evaluated as an antiarrhythmic drug in 49 patients with 78 episodes of premature contractions or tachyarrhythmias of supraventricular or ventricular origin. A clinically and statistically significant reduction in frequency of premature contractions was obtained. In addition, a clinically and statistically significant reduction in ventricular rate occurred in those patients with tachyarrhythmias. No severe adverse effects were noted during the study. The results indicate that alprenolol can be used safely and effectively in the treatment of cardiac arrhythmias occurring during acute myocardial infarction. Congestive heart failure was not considered a contraindication when it was judged clinically that the arrhythmia aggravated the heart failure.",
author = "Louis Lemberg and Arcebal, {Azucena G.} and Agustin Castellanos and Douglas Slavin",
year = "1972",
month = "7",
day = "11",
doi = "10.1016/0002-9149(72)90129-4",
language = "English (US)",
volume = "30",
pages = "77--81",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Use of alprenolol in acute cardiac arrhythmias

AU - Lemberg, Louis

AU - Arcebal, Azucena G.

AU - Castellanos, Agustin

AU - Slavin, Douglas

PY - 1972/7/11

Y1 - 1972/7/11

N2 - Alprenolol, a new beta adrenergic receptor blocking agent, was evaluated as an antiarrhythmic drug in 49 patients with 78 episodes of premature contractions or tachyarrhythmias of supraventricular or ventricular origin. A clinically and statistically significant reduction in frequency of premature contractions was obtained. In addition, a clinically and statistically significant reduction in ventricular rate occurred in those patients with tachyarrhythmias. No severe adverse effects were noted during the study. The results indicate that alprenolol can be used safely and effectively in the treatment of cardiac arrhythmias occurring during acute myocardial infarction. Congestive heart failure was not considered a contraindication when it was judged clinically that the arrhythmia aggravated the heart failure.

AB - Alprenolol, a new beta adrenergic receptor blocking agent, was evaluated as an antiarrhythmic drug in 49 patients with 78 episodes of premature contractions or tachyarrhythmias of supraventricular or ventricular origin. A clinically and statistically significant reduction in frequency of premature contractions was obtained. In addition, a clinically and statistically significant reduction in ventricular rate occurred in those patients with tachyarrhythmias. No severe adverse effects were noted during the study. The results indicate that alprenolol can be used safely and effectively in the treatment of cardiac arrhythmias occurring during acute myocardial infarction. Congestive heart failure was not considered a contraindication when it was judged clinically that the arrhythmia aggravated the heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0015502832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015502832&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(72)90129-4

DO - 10.1016/0002-9149(72)90129-4

M3 - Article

C2 - 4402503

AN - SCOPUS:0015502832

VL - 30

SP - 77

EP - 81

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -